Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
Holding KYMR?
Track your performance easily
KYMR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.96 - $53.27
Previous Close$51.84
Volume308.53K
Average Volume (3M)412.59K
Market Cap
$3.36B
Enterprise Value$2.90B
Total Cash (Recent Filing)$549.97M
Total Debt (Recent Filing)$88.23M
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Feb 20, 2025EPS Estimate
-$0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.33
Shares Outstanding64,765,274
10 Day Avg. Volume429,601
30 Day Avg. Volume412,592
Standard Deviation0.24
R-Squared0.19
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)3.76
Price to Sales (P/S)37.68
Price to Cash Flow (P/CF)-16.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue33.07
Enterprise Value/Gross Profit36.84
Enterprise Value/Ebitda-17.99
Forecast
1Y Price Target
$57.31Price Target Upside14.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Kymera Therapeutics News
PremiumCompany Announcements
Kymera Therapeutics Reports Q3 2024 Earnings and Strategic ShiftBulls Say, Bears Say
Bulls Say
Competitive AdvantageKymera's STAT6 degrader is better than Recludix's inhibitor: 100x more potent, similar on T cell reduction, better on B cell reduction, similar on IgE reduction, better on eosinophil reduction.
Drug Development ProgressKYMR's oral STAT6 degrader KT-621, which recently entered Phase 1, is expected to be the next major inflection point for the stock.
Market PotentialThe potential of KT-621 to be an oral version of the mega-blockbuster product Dupixent is highlighted as a significant opportunity.
Bears Say
Clinical TrialsThe risk/reward on the Phase 1 data is skewed negative due to the potential for an unexpected safety signal, which could lead to setbacks in the development of KT-621.
Research And DevelopmentDe-prioritization of the oncology programs may signal a shift away from potentially lucrative cancer treatments, impacting future growth prospects.
ValuationShares appear fully valued at current levels, suggesting limited upside potential and making them less attractive for new investments.
---
Ownership Overview
28.25% Insiders
28.57% Mutual Funds
1.49% Other Institutional Investors
28.41% Public Companies and
Individual Investors
KYMR FAQ
What was Kymera Therapeutics’s price range in the past 12 months?
Kymera Therapeutics lowest stock price was $13.96 and its highest was $53.27 in the past 12 months.
What is Kymera Therapeutics’s market cap?
Currently, no data Available
When is Kymera Therapeutics’s upcoming earnings report date?
Kymera Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 99 days.
How were Kymera Therapeutics’s earnings last quarter?
Kymera Therapeutics released its earnings results on Oct 31, 2024. The company reported -$0.82 earnings per share for the quarter, beating the consensus estimate of -$0.832 by $0.012.
Is Kymera Therapeutics overvalued?
According to Wall Street analysts Kymera Therapeutics’s price is currently Undervalued.
Does Kymera Therapeutics pay dividends?
Kymera Therapeutics does not currently pay dividends.
What is Kymera Therapeutics’s EPS estimate?
Kymera Therapeutics’s EPS estimate is -$0.77.
How many shares outstanding does Kymera Therapeutics have?
Kymera Therapeutics has 64,765,274 shares outstanding.
What happened to Kymera Therapeutics’s price movement after its last earnings report?
Kymera Therapeutics reported an EPS of -$0.82 in its last earnings report, beating expectations of -$0.832. Following the earnings report the stock price went down -3.147%.
Which hedge fund is a major shareholder of Kymera Therapeutics?
Among the largest hedge funds holding Kymera Therapeutics’s share is Baker Bros Advisors LP. It holds Kymera Therapeutics’s shares valued at 179M.
---
Kymera Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.31 (14.62% Upside)
$57.31 (14.62% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 223.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $46.4 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
257.02%
12-Months-Change
Fundamentals
Return on Equity
-26.00%
Trailing 12-Months
Asset Growth
87.34%
Trailing 12-Months
Company Description
Kymera Therapeutics
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade the intractable of proteins, and advance new treatment options for patients.
---
KYMR Earnings Call
Q3 2024
0:00 / 0:00
---
KYMR Stock 12 Month Forecast
Average Price Target
$57.31
▲(14.62% Upside)
Technical Analysis
Best Analysts Covering KYMR
1 Year
1 Year Success Rate
8/8 ratings generated profit
1 Year Average Return
+72.31%
assigned a buy rating 12 days ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +72.31% per trade.
---